Telix Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
1,184
- Stock Symbol
-
TLX
- Investments
-
17
- Share Price
-
$8.60
- (As of Friday Closing)
Telix Pharmaceuticals General Information
Description
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Contact Information
Website
www.telixpharma.comCorporate Office
- 55 Flemington Road
- Level 4
- North Melbourne, Victoria 3051
- Australia
Corporate Office
- 55 Flemington Road
- Level 4
- North Melbourne, Victoria 3051
- Australia
Telix Pharmaceuticals Stock Performance
As of 20-Nov-2026, Telix Pharmaceuticals’s stock price is $8.60. Its current market cap is $2.92B with 340M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.60 | $8.87 | $5.84 - $13.00 | $2.92B | 340M | 2.09M | $0.10 |
Telix Pharmaceuticals Financials Summary
As of 30-Jun-2026, Telix Pharmaceuticals has a trailing 12-month revenue of $891M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,199,873 | 2,725,850 | 5,062,230 | 2,146,340 |
| Revenue | 890,785 | 803,794 | 516,551 | 332,978 |
| EBITDA | 68,097 | 29,324 | 54,885 | 10,866 |
| Net Income | 33,497 | (7,125) | 33,685 | 4,208 |
| Total Assets | 1,361,851 | 1,163,986 | 940,379 | 277,258 |
| Total Debt | 579,861 | 467,106 | 360,162 | 12,264 |
Telix Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Telix Pharmaceuticals Comparisons
Industry
Financing
Details
Telix Pharmaceuticals Competitors (6)
One of Telix Pharmaceuticals’s 6 competitors is Sermonix Pharmaceuticals, a Venture Capital-Backed company based in Columbus, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sermonix Pharmaceuticals | Venture Capital-Backed | Columbus, OH | ||||
| Clarity Pharmaceuticals | Formerly VC-backed | Eveleigh, Australia | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| AdvanCell | Venture Capital-Backed | Boston, MA | ||||
| Cantex Pharmaceuticals | Formerly VC-backed | Weston, FL |
Telix Pharmaceuticals Patents
Telix Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026059931-A2 | Dll3 antigen binding constructs | Pending | 11-Sep-2024 | ||
| WO-2026059931-A3 | Dll3 antigen binding constructs | Pending | 11-Sep-2024 | ||
| AU-2025310414-A1 | Antibodies and methods of making and using same | Pending | 26-Jul-2024 | ||
| WO-2026024987-A1 | Antibodies and methods of making and using same | Pending | 26-Jul-2024 | ||
| AU-2024346987-A1 | Antigen binding constructs | Pending | 19-Sep-2023 | C07K16/00 |
Telix Pharmaceuticals Signals
Telix Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Telix Pharmaceuticals Investments & Acquisitions (17)
Telix Pharmaceuticals’s most recent deal was a Merger/Acquisition with ITM Isotope Technologies Munich for . The deal was made on 21-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ITM Isotope Technologies Munich | 21-Sep-2026 | Merger/Acquisition | Biotechnology | ||
| Telix Innovations Brazil | 17-Mar-2025 | Joint Venture | Pharmaceuticals | ||
| SCV (Fibroblast Activation Protein Located in Germany) | 12-Mar-2025 | Corporate Asset Purchase | Buildings and Property | ||
| ImaginAb (Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform) | 30-Jan-2025 | Corporate Asset Purchase | Buildings and Property | ||
| RLS Radiopharmacies | 28-Jan-2025 | Merger/Acquisition | Specialty Retail |
Telix Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
29.83 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Telix Pharmaceuticals Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| RLS Radiopharmacies | Lake Mary, FL | 2019 | |
| Dedicaid | Vienna, Austria | 2018 | |
| Optimal Tracers | Sacramento, CA | 2013 | |
| ARTMS | Burnaby, Canada | 2013 | |
| Lightpoint Medical | Amersham, United Kingdom | 2012 |
Telix Pharmaceuticals FAQs
-
When was Telix Pharmaceuticals founded?
Telix Pharmaceuticals was founded in 2015.
-
Where is Telix Pharmaceuticals headquartered?
Telix Pharmaceuticals is headquartered in North Melbourne, Australia.
-
What is the size of Telix Pharmaceuticals?
Telix Pharmaceuticals has 1,184 total employees.
-
What industry is Telix Pharmaceuticals in?
Telix Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Telix Pharmaceuticals a private or public company?
Telix Pharmaceuticals is a Public company.
-
What is Telix Pharmaceuticals’s stock symbol?
The ticker symbol for Telix Pharmaceuticals is TLX.
-
What is the current stock price of Telix Pharmaceuticals?
As of 20-Nov-2026 the stock price of Telix Pharmaceuticals is $8.60.
-
What is the current market cap of Telix Pharmaceuticals?
The current market capitalization of Telix Pharmaceuticals is $2.92B.
-
What is Telix Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Telix Pharmaceuticals is $891M.
-
Who are Telix Pharmaceuticals’s competitors?
Sermonix Pharmaceuticals, Clarity Pharmaceuticals, Gilead, AdvanCell, and Cantex Pharmaceuticals are some of the 6 competitors of Telix Pharmaceuticals.
-
What is Telix Pharmaceuticals’s annual earnings per share (EPS)?
Telix Pharmaceuticals’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process